Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 89

Similar articles for PubMed (Select 15980612)

1.

ELISA method for measurement of amyloid-beta levels.

Schmidt SD, Nixon RA, Mathews PM.

Methods Mol Biol. 2005;299:279-97.

PMID:
15980612
2.

Aβ measurement by enzyme-linked immunosorbent assay.

Schmidt SD, Mazzella MJ, Nixon RA, Mathews PM.

Methods Mol Biol. 2012;849:507-27. doi: 10.1007/978-1-61779-551-0_34.

PMID:
22528112
3.

Biochemical detection of Abeta isoforms: implications for pathogenesis, diagnosis, and treatment of Alzheimer's disease.

Golde TE, Eckman CB, Younkin SG.

Biochim Biophys Acta. 2000 Jul 26;1502(1):172-87. Review.

4.

Amyloid precursor protein processing and retinal pathology in mouse models of Alzheimer's disease.

Dutescu RM, Li QX, Crowston J, Masters CL, Baird PN, Culvenor JG.

Graefes Arch Clin Exp Ophthalmol. 2009 Sep;247(9):1213-21. doi: 10.1007/s00417-009-1060-3. Epub 2009 Mar 7.

PMID:
19271231
5.

Reduced levels of amyloid beta-peptide antibody in Alzheimer disease.

Du Y, Dodel R, Hampel H, Buerger K, Lin S, Eastwood B, Bales K, Gao F, Moeller HJ, Oertel W, Farlow M, Paul S.

Neurology. 2001 Sep 11;57(5):801-5.

PMID:
11552007
6.

A comparative analysis of brain and plasma Abeta levels in eight common non-transgenic mouse strains: validation of a specific immunoassay for total rodent Abeta.

Yohrling GJ, Felsenstein KM, Conway KA, Zupa-Fernandez A, Brenneman DE, Arnold HM.

Curr Alzheimer Res. 2007 Jul;4(3):297-303.

PMID:
17627487
7.

The levels of soluble versus insoluble brain Abeta distinguish Alzheimer's disease from normal and pathologic aging.

Wang J, Dickson DW, Trojanowski JQ, Lee VM.

Exp Neurol. 1999 Aug;158(2):328-37.

PMID:
10415140
8.

High throughput screens for the identification of compounds that alter the accumulation of the Alzheimer's amyloid beta peptide (Abeta).

Haugabook SJ, Yager DM, Eckman EA, Golde TE, Younkin SG, Eckman CB.

J Neurosci Methods. 2001 Jul 30;108(2):171-9.

PMID:
11478976
9.

Development of Abeta terminal end-specific antibodies and sensitive ELISA for Abeta variant.

Horikoshi Y, Sakaguchi G, Becker AG, Gray AJ, Duff K, Aisen PS, Yamaguchi H, Maeda M, Kinoshita N, Matsuoka Y.

Biochem Biophys Res Commun. 2004 Jul 2;319(3):733-7.

PMID:
15184044
10.

Dynamics of Abeta turnover and deposition in different beta-amyloid precursor protein transgenic mouse models following gamma-secretase inhibition.

Abramowski D, Wiederhold KH, Furrer U, Jaton AL, Neuenschwander A, Runser MJ, Danner S, Reichwald J, Ammaturo D, Staab D, Stoeckli M, Rueeger H, Neumann U, Staufenbiel M.

J Pharmacol Exp Ther. 2008 Nov;327(2):411-24. doi: 10.1124/jpet.108.140327. Epub 2008 Aug 7.

11.

[Alzheimer disease: cellular and molecular aspects].

Octave JN.

Bull Mem Acad R Med Belg. 2005;160(10-12):445-9; discussion 450-1. French.

PMID:
16768248
12.

BACE1 inhibition reduces endogenous Abeta and alters APP processing in wild-type mice.

Nishitomi K, Sakaguchi G, Horikoshi Y, Gray AJ, Maeda M, Hirata-Fukae C, Becker AG, Hosono M, Sakaguchi I, Minami SS, Nakajima Y, Li HF, Takeyama C, Kihara T, Ota A, Wong PC, Aisen PS, Kato A, Kinoshita N, Matsuoka Y.

J Neurochem. 2006 Dec;99(6):1555-63. Epub 2006 Nov 2.

PMID:
17083447
13.

P-glycoprotein efflux and other factors limit brain amyloid beta reduction by beta-site amyloid precursor protein-cleaving enzyme 1 inhibitors in mice.

Meredith JE Jr, Thompson LA, Toyn JH, Marcin L, Barten DM, Marcinkeviciene J, Kopcho L, Kim Y, Lin A, Guss V, Burton C, Iben L, Polson C, Cantone J, Ford M, Drexler D, Fiedler T, Lentz KA, Grace JE Jr, Kolb J, Corsa J, Pierdomenico M, Jones K, Olson RE, Macor JE, Albright CF.

J Pharmacol Exp Ther. 2008 Aug;326(2):502-13. doi: 10.1124/jpet.108.138974. Epub 2008 May 22.

14.
15.

Vascular endothelial growth factor (VEGF) affects processing of amyloid precursor protein and beta-amyloidogenesis in brain slice cultures derived from transgenic Tg2576 mouse brain.

Bürger S, Noack M, Kirazov LP, Kirazov EP, Naydenov CL, Kouznetsova E, Yafai Y, Schliebs R.

Int J Dev Neurosci. 2009 Oct;27(6):517-23. doi: 10.1016/j.ijdevneu.2009.06.011. Epub 2009 Jul 7.

PMID:
19589380
16.

Development of a specific ELISA for the quantitative study of amino-terminally truncated beta-amyloid peptides.

El Mouedden M, Vandermeeren M, Meert T, Mercken M.

J Neurosci Methods. 2005 Jun 30;145(1-2):97-105. Epub 2005 Jan 8.

PMID:
15922029
17.

Transplanted astrocytes internalize deposited beta-amyloid peptides in a transgenic mouse model of Alzheimer's disease.

Pihlaja R, Koistinaho J, Malm T, Sikkilä H, Vainio S, Koistinaho M.

Glia. 2008 Jan 15;56(2):154-63.

PMID:
18004725
18.

Amyloid-beta oligomers are inefficiently measured by enzyme-linked immunosorbent assay.

Stenh C, Englund H, Lord A, Johansson AS, Almeida CG, Gellerfors P, Greengard P, Gouras GK, Lannfelt L, Nilsson LN.

Ann Neurol. 2005 Jul;58(1):147-50.

PMID:
15984012
19.

The redox chemistry of the Alzheimer's disease amyloid beta peptide.

Smith DG, Cappai R, Barnham KJ.

Biochim Biophys Acta. 2007 Aug;1768(8):1976-90. Epub 2007 Feb 9. Review.

20.

Cytoplasmic gelsolin increases mitochondrial activity and reduces Abeta burden in a mouse model of Alzheimer's disease.

Antequera D, Vargas T, Ugalde C, Spuch C, Molina JA, Ferrer I, Bermejo-Pareja F, Carro E.

Neurobiol Dis. 2009 Oct;36(1):42-50. doi: 10.1016/j.nbd.2009.06.018. Epub 2009 Jul 14.

PMID:
19607917
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk